Loading...
•
Dec 31, 2024
Bausch Health Q4 2024 Earnings Report
Bausch Health reported strong Q4 2024 performance, with revenue growth and improved profitability.
Key Takeaways
Bausch Health achieved its seventh consecutive quarter of year-over-year growth, reporting Q4 revenue of $2.56 billion, up 6%. Adjusted net income increased to $430 million, while GAAP net income reached $93 million. The company showed strong performance in the Solta Medical and Bausch + Lomb segments, with significant revenue growth.
Q4 2024 revenue reached $2.56 billion, a 6% increase year-over-year.
GAAP net income was $93 million, compared to a net loss of $39 million in Q4 2023.
Adjusted net income increased to $430 million, reflecting operational improvements.
Solta Medical and Bausch + Lomb segments led revenue growth with 34% and 9% increases, respectively.
Bausch Health
Bausch Health
Bausch Health Revenue by Segment
Revenue by Segment
Bausch + Lomb/International Revenue
CapyFin.comSalix Revenue
CapyFin.comDiversified Products Revenue
CapyFin.com Forward Guidance
Bausch Health expects continued revenue and adjusted EBITDA growth in 2025, driven by expansion across its business segments.
Positive Outlook
- Revenue projected between $9.90 billion and $10.15 billion.
- Expected revenue growth of 2% to 6% year-over-year.
- Adjusted EBITDA projected between $3.525 billion and $3.675 billion.
- Bausch + Lomb segment expected to maintain strong growth trajectory.
- Continued strategic investments in research and development.
Challenges Ahead
- Uncertainty due to macroeconomic conditions and foreign exchange fluctuations.
- Higher selling, general, and administrative expenses could impact profitability.
- Competitive pressures in key segments such as neurology and dermatology.
- Potential regulatory challenges affecting product approvals.
- Debt obligations and interest expenses remain significant considerations.